Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $1.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 0.81% from the stock’s current price.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other equities analysts also recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $2.46.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. Quantitative Investment Management LLC acquired a new stake in Regulus Therapeutics in the second quarter worth approximately $103,000. GSA Capital Partners LLP acquired a new stake in Regulus Therapeutics in the second quarter worth approximately $139,000. FMR LLC lifted its position in Regulus Therapeutics by 0.5% in the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares during the period. Goldman Sachs Group Inc. lifted its position in Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 240,890 shares during the period. Finally, Royal Bank of Canada lifted its position in Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 19,934 shares during the period. Hedge funds and other institutional investors own 59.39% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.